John W. Walsh Alpha-1 Home Infusion Act of 2025
This bill has not become law. Status shown reflects the latest official action.
See what this could mean for your district
Save your district in Account to view district-specific context for this bill.
Bill details
Summary
Introduced in House
John W. Walsh Alpha-1 Home Infusion Act of 2025 This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
District impact notes
No impact notes have been generated for this bill yet.
These impact notes are AI-generated from official bill metadata/summary as a prototype feature — not official government language.
Related votes
Roll calls that reference this bill in official data.
Primary sources
Official links to verify details. (No interpretation.)
About this data
- OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
- Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
- District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
- This page updates automatically via a daily ingestion pipeline.